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Prostanoids, which include prostaglandin and thromboxane, are metabolites of arachidonic acid released
in various pathophysiological conditions. They induce a range of actions mediated through their
respective receptors expressed on target cells. It has been demonstrated that each prostanoid receptor
has multiple functions and that the effect of receptor stimulation can vary depending on context; this
sometimes results in opposing effects, such as simultaneous excitatory and inhibitory outcomes. The
balance between the production of each prostanoid and the expression of its receptors has been shown
to be important for maintaining homeostasis but also involved in the development of various patho-
logical conditions such as allergy. Here, we review the recent ﬁndings on the roles of prostanoids in
allergy, especially focusing on atopic dermatitis and asthma.
Copyright © 2014, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.Introduction
When tissues are exposed to diverse pathophysiological stimuli,
arachidonic acid (AA) is released from membrane phospholipids
and converted into lipid mediators, such as prostanoids, leukotri-
enes (LT) and hydroxy-eicosatetraenoic acids (HETEs) via their
respective synthases.1 Prostanoids are formed by the cyclo-
oxygenase (COX) pathway.1 COX has two isoforms, COX-1 and COX-
2. While COX-1 is constitutively expressed in cells, COX-2 requires
speciﬁc stimulation by substances such as acetone and phorbol
ester. The COX reaction results in the formation of an unstable
endoperoxide intermediate called prostaglandin (PG) H2, which, in
turn, is metabolized to PGD2, PGE2, PGF2a, PGI2, and thromboxane
(TX) A2 by their speciﬁc synthases1 (Fig. 1).
Prostanoids are released from cells immediately after formation.
Since they are chemically and metabolically unstable, they usually
function only locally through membrane receptors on target cells.1
Nine types and subtypes of membrane prostanoid receptors are
conserved in mammals frommouse to human: two subtypes of the
PGD receptor (DP (DP1) and a chemoattractant receptor
homologous-molecule expressed on Th2 cells known as CRTH2
(DP2)),2 four subtypes of the PGE receptor (EP1, EP2, EP3, and EP4),




rgology. Production and hosting by Els(TP)1 (Fig. 1). All are G proteinecoupled rhodopsin-type receptors
with seven transmembrane domains.
Although it has been difﬁcult to analyze the physiological roles
of prostanoids because of their instability in vivo, recent de-
velopments in both the disruption of the respective genes and the
creation of receptor-selective compounds have made it possible.3,4
These genetic and pharmacological approaches have revealed new
roles played by prostanoids and their receptors in allergic diseases.
In this review, we describe the current state of our knowledge of
prostanoids' roles in atopic dermatitis and asthma.
Prostanoids in atopic dermatitis (allergy, skin barrier
functions, pruritus)
Atopic dermatitis (AD) is a common chronic inﬂammatory skin
disease characterized by a complex, heterogeneous pathogenesis,
including allergy/immunology, skin barrier dysfunction, and pru-
ritus.5e7 In the dermis, a cellular inﬁltrate is present consisting of
lymphocytes, monocytes and mast cells.
It has been reported that several kinds of prostanoids including
PGE2 and PGD2 are produced in the skin of AD patients.8e10 Yet the
roles of the various prostanoids in the pathogenesis of AD have not
been thoroughly pursued, because treatment with COX inhibitors,
which block the production of prostanoids, are not usually effective
against AD symptoms, implicating a weaker association of prosta-
noids with the pathogenesis of AD. However, recent studies have
suggested that various prostanoid receptors do play distinct stim-
ulatory and regulatory functions in the pathogenesis of AD.evier B.V. All rights reserved.
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Fig. 1. Prostanoids synthesis and receptors. Prostanoids synthesis pathways, their respective receptors, and the signal transduction mechanisms from the receptors. Gs is a
heterotrimeric G protein subunits that activates adenylate cyclase, which produces cAMP, and activates cAMP-dependent protein kinase. Gi is also a heterotrimeric G protein
subunits that inhibits the production of cAMP, and Gq activates phospholipase C and increases the cytosolic calcium concentration. PG, Prostaglandin; COX, cyclooxygenase; NSAIDs,
Non-steroidal anti-inﬂammatory drugs; HETEs, hydroxy-eicosatetraenoic acids.
T. Honda, K. Kabashima / Allergology International 64 (2015) 11e1612Prostanoids in immunology of AD
Recently, several new types of murine AD models have been
established,11 including an ovalbumin (OVA)-induced mouse AD
model12 and a repeated hapten application contact hypersensitivity
(CHS) model.13 In an OVA-induced mouse AD model, COX-2-
deﬁcient mice exhibited both enhanced eosinophil inﬁltration
and elevated IL-4 expression in the skin and spleen with elevated
serum antigen-speciﬁc IgE and IgG1,14 suggesting the existence of
prostanoid receptors that have regulatory functions in AD.
Among the prostanoids, PGD2 is the major prostanoid produced
by activated mast cells. It is detected in the skin of AD pa-
tients9,10,15,16 as well as in the OVA-induced AD model.17 PGD2
production in skin can also be stimulated by scratching, however.18
Because local application of PGD2 induces peripheral vasodilation,
while systemic injection of PGD2 induces ﬂushing and nasal
congestion, it has generally been believed that PGD2 acts as an
inﬂammatory mediator in AD.19 However, recent studies have
revealed that PGD2 plays both pro- and anti-inﬂammatory roles in
cutaneous immune responses depending on the receptors.
PGD2 has two types of receptors, DP1 and CRTH2.2 In an OVA-
induced AD model, administration of BW245c, a DP agonist, in-
hibits sensitization with OVA by inhibiting the migration of skin
dendritic cells (DC).20,21 Consistently, DP-deﬁcient mice exhibit
enhanced inﬂammation in the AD model of repeated hapten
application and CHS, with increased skin DC migration to draining
LNs,22 suggesting that PGD2-DP signaling exerts a regulatory role in
the development of AD. Even in a more acute skin inﬂammation
model, it is reported that PGD2-DP signaling plays suppressive roles
by enhancing vascular endothelial barrier function.23
PGD2-CRTH2 signaling, on the other hand, generally plays pro-
inﬂammatory roles in skin inﬂammation. CRTH2 induces chemo-
taxis in Th2 cells, neutrophils, eosinophils and basophils with
enhanced degranulation.2,24,25 These chemotactic effects have been
conﬁrmed in several skin inﬂammation models. CRTH2-deﬁcientmice exhibit normal sensitization but reduced eosinophil and
CD4þ T cell inﬁltration in the OVA-induced AD model.17 CRTH2-
deﬁcient mice also exhibit reduced inﬂammation in CHS22,26 as
well as the repeated hapten application AD model26,27 and a croton
oil-induced acute skin inﬂammation model.23 Basophil inﬁltration
into the skin is signiﬁcantly impaired in CRTH2-deﬁcient mice in an
IgE-mediated chronic allergic skin inﬂammation model.26 Consis-
tently, administration of a CRTH2 antagonist inhibits neutrophil
inﬁltration into the skin and attenuates the CHS response25 and the
OVA-induced AD model.28 In humans, virtually all CRTH2þ CD4þ
lymphocytes have a pure Th2 phenotype; they constitute not all but
a large proportion of circulating Th2 cells in both normal and AD
subjects.29,30 In AD subjects, a preferential increase in CRTH2þ cells
was noted within the disease-related cutaneous lymphocyte-
associated antigen-positive CD4þ T cell compartment.30 These re-
sults suggest the importance of CRTH2 in Th2 cell, neutrophil,
eosinophil and basophil inﬁltration or activation in cutaneous
allergic disease including AD.
Recently, the class of innate lymphoid cells (ILCs) known as type
2 ILC (ILC2) has been identiﬁed in various tissues such as skin, lung,
and intestine.31 ILC2 are responsive to IL-25 or IL-33, and abun-
dantly produce type 2 cytokines such as IL-5 and IL-13. ILC2 are
supposed to play signiﬁcant roles in the development of allergic
diseases such as asthma or atopic dermatitis.32 Human ILC2 have
been shown to express CRTH2.33 Furthermore, it has recently been
reported that PGD2 induces type 2 cytokine production and
chemotaxis of ILC2 via CRTH2.34,35 Therefore, an antagonist for
CRTH2 may inhibit not only Th2 cells and eosinophils but also the
recruitment of ILC2 into tissues.
In addition to its direct chemotactic effects, PGD2 has recently
been reported to mediate eosinophil skin inﬁltration indirectly by
inducing eotaxin-3 production from sebocytes.36
To summarize, PGD2 seems to play some pro-inﬂammatory roles
and some anti-inﬂammatory roles in the pathogenesis of AD,
through DP and CRTH2, respectively.
T. Honda, K. Kabashima / Allergology International 64 (2015) 11e16 13PGE2 is also detected abundantly in the skin of AD.8 PGE2 has
four subtypes of receptors; EP1, EP2, EP3, and EP4. Like PGD2,
PGE2 has been assumed to be an important mediator in acute
skin inﬂammation. In fact, vasodilation in ultraviolet (UV) B-
induced dermatitis is mediated through EP2 and EP4 receptors.37
In an arachidonic acid-induced dermatitis model, PGE2-EP3
signaling mediates this process by inducing mast cell activation
and subsequent histamine release and IL-6 production.38,39
Nevertheless, the role of each PGE receptor in AD remains un-
clear. It has been reported, however, that PGE2 receptors exert
various important roles in cutaneous immune response, sug-
gesting the importance of PGE2 receptors in AD. For example,
EP1, EP2 and EP4 signaling on CD4 T cells facilitate Th1 and/or
Th17 differentiation in CHS.40,41 EP4 signaling promotes cuta-
neous DC migration to draining LNs and initiates sensitization in
CHS,42 while EP3 signaling inhibits their migration and regulates
sensitization.43 EP3 also regulates chemokine production from
keratinocytes.44 It has also been reported that EP4 signaling
mediates regulatory T cell induction through upregulation of
RANKL on keratinocytes in a UV-induced immunosuppression
model.45 In in-vitro studies, PGE2 drives Ig class switching to IgE
by acting on EP2 and EP4 on B cells under LPS and IL-4 stimu-
lation.46 These results suggest that PGE2 both suppresses and
aggravates the development of AD.
PGI2 and TxA2 also exert important roles in cutaneous immune
response and might play signiﬁcant roles in AD. PGI2-IP signaling
on naive CD4þ T cells facilitates Th1 differentiation in CHS,47
although the role of PGI2 in Th1/2 differentiation is context-
dependent.48 Cutaneous DCs produce abundant TXA2, which acts
on naïve T cells to impair the DC-T cell interaction and negatively
regulates the priming of T cells.49 TP-deﬁcient mice exhibit
enhanced CHS responses as well as elevated serum IgE in the










Fig. 2. The possible roles of prostanoids in the development of atopic dermatitis. Sch
dermatitis. PG, Prostaglandin; TX, Thromboxane; CRTH2, chemoattractant receptor homologo
cell; dDC, dermal dendritic cell.plays regulatory roles in Th2 cell differentiation or proliferation in
AD. The possible involvement of the various prostanoid receptors in
AD is summarized in Fig. 2.Prostanoids in pruritus
Pruritus is an important hallmark of AD. It has been reported
that PGE2 evokes pruritus in AD patients, probably via histamine
release.50,51 On the other hand, topical application of PGE2 inhibited
spontaneous scratching in NC/Nga mice with chronic derma-
titis.51,52 Topical application of PGD2, but not a CRTH2 agonist, also
reduced scratching behavior in NC/Nga mice, suggesting that DP
suppresses pruritic activity.52 A recent report suggests that, in
addition to PGE2 and PGD2, TxB2 elicits itch through TP on primary
afferents and keratinocytes.53 Although the mechanisms by which
prostanoids regulate pruritus remain largely unknown, regulation
of these lipid mediators or their receptors may offer potential for a
novel antipruritic treatment.Prostanoids in skin barrier functions
Skin barrier function is important to avoid desiccation and to
protect against foreign insults. Two sets of barriers are involved: the
stratum corneum and the tight junction.5 As barrier dysfunction is
thought to be not merely an epiphenomenon of AD but rather the
initiator of AD pathogenesis,5 control of barrier function is impor-
tant for the treatment of AD. So far, the involvement of prostanoids
in skin barrier function remains largely unknown. However, studies
using a mechanical scratching-induced cutaneous barrier disrup-
tion model suggest a protective role of PGD2 in skin barrier func-
tion.54,55 Further detailed analysis may reveal novel functions of













ematic summary of the possible roles of prostanoids in the development of atopic
us-molecule expressed on Th2 cells; ILC2, innate lymphoid cells type 2; LC, Langerhans
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Asthma is a chronic inﬂammation of the conducting airways,
and is characterized by intermittent attacks of breathlessness,
wheezing, and cough.56 Th2 cells, Th2-associated cytokines, eo-
sinophils and basophils mediate the inﬂammation. Involvement of
prostanoids in the pathogenesis of asthma has long been suspected,
because it is well known that ingestion of aspirin, an NSAID that
blocks prostanoid synthesis, sometimes induces severe broncho-
constriction in a proportion of subjects with asthma,57,58 and COX-
2-deﬁcient mice exhibit augmented airway inﬂammation in an
asthma model.59 Previously, the pathogenesis of aspirin-induced
asthmatic attacks (AIA) were explained by the diversion of arach-
idonic acid metabolism from the COX pathway to the LO pathway
and the subsequent elevation of leukotrienes, such as cysteinyl LTs
(CysLT)60,61,62 because CysLTs are strong inducers of bronchocon-
striction63 and tissue eosinophilia.63 However, the loss of inhibitory
signaling from prostanoid receptors may also be involved in the
pathogenesis of AIA.
EP3 receptor is one of the inhibitory receptors that may be
involved in allergy.44,64,65 In an OVA-induced murine asthma
model, EP3-deﬁcient mice exhibited similar levels of serum IgE but
exaggerated airway inﬂammation, and administration of an EP3
agonist suppressed the inﬂammation by inhibiting mast cell acti-
vation and chemokine production from airway epithelial cells.64
EP3 signaling is also reported to play an anti-inﬂammatory role in
experimental allergic conjunctivitis by inhibiting chemokine pro-
duction from the conjunctival epithelium.65 These results indicate














Fig. 3. The possible roles of prostanoids in the development of asthma. Schematic sum
glandin; CRTH2, chemoattractant receptor homologous-molecule expressed on Th2 cells; Dduring the effector phase. One recent study suggests that, in
addition to EP3, endogenous PGE2-EP2 signaling also exerts regu-
latory effects in the development of asthma.66 EP2-deﬁcient mice
exhibit an exaggerated phenotype with elevated serum IgE levels,
and administration of an EP2 agonist during the sensitization phase
reduces the IL-4 or IL-13 production from CD4þ T cells and reduces
airway inﬂammation.66 In addition, a polymorphism in EP2 gene is
reported to be associated with AIA.67 These results suggest that EP2
plays suppressive roles during the sensitization phase. Intriguingly,
it has been reported that IP-deﬁcient mice also exhibit elevated
serum IgE levels and exaggerated airway inﬂammation.68 Signaling
from EP2 and IP facilitates Th1 differentiation through the elevation
of cAMP,40,47,69 which may explain the enhanced Th2 response in
EP2-deﬁcient mice and IP-deﬁcient mice.
PGD2 is a major prostanoid produced by activated mast cells70
and is released in large amounts during asthmatic attacks in
certain patients.71 Although the role of PGD2 in allergic asthma long
remained unclear, an analysis using DP-deﬁcientmice revealed that
PGD2-DP signaling stimulates chemokine expression in airway
epithelial cells, facilitates Th2 cell and eosinophil accumulation in
the lungs, and plays a central role in asthma.70 On the other hand, it
has also been reported that administration of a DP agonist during
the sensitization phase suppresses airway inﬂammation by inhib-
iting DC migration and induction of regulatory T cells.72,73 These
results suggest that DP signaling plays regulatory roles in the
sensitization phase but exerts pro-inﬂammatory roles in the
effector phase of asthma (Fig. 3). The involvement of DP in the
pathogenesis of asthma is also suggested by the results of human








mary on the possible roles of prostanoids in the development of asthma. PG, Prosta-
C, dendritic cell; Treg, regulatory T cell.
T. Honda, K. Kabashima / Allergology International 64 (2015) 11e16 15PGD2-CRTH2 signaling may also contribute to the development
of asthma. Administration of a CRTH2 antagonist reduced eosino-
phil accumulation in a mouse asthma model, and administration of
a CRTH2 agonist augmented the inﬁltration of inﬂammatory cells
into the lungs,75,76 suggesting that PGD2-CRTH2 signaling mediates
airway inﬂammation. However, it has been reported that CRTH2-
deﬁcient mice exhibited increased inﬂammatory cell inﬁltration
and IL-5 production from activated T lymphocytes,77 suggesting
that CRTH2 signaling regulates cytokine production in the devel-
opment of asthma. Further analyses are needed to clarify whether
inhibition of CRTH2 signaling would have an overall beneﬁcial
effect.
Conclusions
In this review, we have summarized current ﬁndings on the
actions of prostanoid receptors in allergic diseases. Although the
role of each lipid mediator is various and complex, selective
manipulation of the actions mediated by each receptor may lead to
the discovery of a novel therapeutic strategy for allergic disorders.
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